Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 133, Issue 1, 2013, Pages 30-42

  Gupta, Akash ^a   Mehta, Rajeshwari ^a   Alimirah, Fatouma ^a   Peng, Xinjian ^a   Murillo, Genoveva ^a   Wiehle, Ronald ^b   Mehta, Rajendra G ^a  

^a IIT RESEARCH INSTITUTE   (United States)

^b Repros Therapeutics   (United States)

Author keywords

Antiprogestin; Aromatase inhibitor; Breast cancer

Indexed keywords

ANASTROZOLE; AROMATASE; ESTRADIOL; EXEMESTANE; LETROZOLE; MESSENGER RNA; TELAPRISTONE ACETATE; TESTOSTERONE;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC ACTIVITY; AROMATIZATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAR WESTERN BLOTTING; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BASE SEQUENCE; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENES, ERBB-1; HUMANS; NITRILES; NORPREGNADIENES; PROGESTINS; PROMEGESTONE; RECEPTORS, PROGESTERONE; RNA, MESSENGER; RNA, NEOPLASM; TAMOXIFEN; TESTOSTERONE; TRIAZOLES; TUMOR STEM CELL ASSAY;

EID: 84866987587     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.08.004     Document Type: Article

References (52)

1. H.A. Azim Jr., and M.J. Piccart Simultaneous targeting of estrogen receptor and HER2 in breast cancer Expert Review of Anticancer Therapy 10 8 2010 1255 1263
2. I.P. Uray, and P.H. Brown Chemoprevention of hormone receptor-negative breast cancer: new approaches needed Recent Results in Cancer Research 188 2011 147 162
3. A. Prat, and J. Baselga The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 Nature Clinical Practice. Oncology 5 9 2008 531 542
4. C.A. Lamb, L.A. Helguero, V. Fabris, C. Lucas, A.A. Molinolo, and C. Lanari Differential effects of raloxifene, Tamoxifen and fulvestrant on a murine mammary carcinoma Breast Cancer Research and Treatment 79 1 2003 25 35
5. R. Kudachadkar, and R.M. O'Regan Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer CA: A Cancer Journal for Clinicians 55 3 2003 145 163
6. A. Brodie, G. Sabnis, and D. Jelovac Aromatase and breast cancer Journal of Steroid Biochemistry and Molecular Biology 102 1-5 2006 97 102
7. P. Conte, and A. Frassoldati Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective The Breast Journal 13 1 2007 28 35
8. T. Petit, P. Dufour, and I. Tannock A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer Endocrine-related Cancer 18 3 2011 R79 R89
9. C. Dunn, and S.J. Keam Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer Pharmacoeconomics 24 5 2006 495 517
10. H.D. Nelson, R. Fu, J.C. Griffin, P. Nygren, M.E. Smith, and L. Humphrey Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer Annals of Internal Medicine 151 10 2009 703 715 W-226-35
11. V.C. Jordan, and B.W. O'Malley Selective estrogen-receptor modulators and antihormonal resistance in breast cancer Journal of Clinical Oncology 25 36 2007 5815 5824
12. O. Mc Cormack, M. Harrison, M.J. Kerin, and A. McCann Role of the progesterone receptor (PR) and the PR isoforms in breast cancer Critical Reviews in Oncogenesis 13 4 2007 283 301
13. A. Fournier, A. Fabre, S. Mesrine, M.C. Boutron-Ruault, F. Berrino, and F. Clavel-Chapelon Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer Journal of Clinical Oncology 26 8 2008 1260 1268
14. M.L. Stefanick, G.L. Anderson, K.L. Margolis, S.L. Hendrix, R.J. Rodabough, E.D. Paskett, D.S. Lane, F.A. Hubbell, A.R. Assaf, G.E. Sarto, R.S. Schenken, S. Yasmeen, L. Lessin, R.T. Chlebowski, and WHI Investigators Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy The Journal of the American Medical Association 295 14 2006 1647 1657
15. E.C. Kordon, A.A. Molinolo, C.D. Pasqualini, E.H. Charreau, P. Pazos, G. Dran, and C. Lanari Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between progestin dependence and morphology Breast Cancer Research and Treatment 28 1 1993 29 39
16. E.A. Musgrove, C.S. Lee, and R.L. Sutherland Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes Molecular and Cellular Biology 11 10 1991 5032 5043
17. C.A. Lange, J.K. Richer, T. Shen, and K.B. Horwitz Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways Journal of Biological Chemistry 273 47 1998 31308 31316
18. J.R. Schultz, L.N. Petz, and A.M. Nardulli Estrogen receptor alpha and Sp1 regulate progesterone receptor gene expression Molecular and Cellular Endocrinology 201 1-2 2003 165 175
19. T. Flötotto, D. Niederacher, D. Hohmann, T. Heimerzheim, P. Dall, S. Djahansouzi, H.G. Bender, and B. Hanstein Molecular mechanism of estrogen receptor (ER) alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform Journal of Steroid Biochemistry and Molecular Biology 88 2 2004 131 142
20. S.A. Leonhardt, and D.P. Edwards Mechanism of action of progesterone antagonists Experimental Biology and Medicine (Maywood) 227 11 2002 969 980
21. B.J. Attardi, J. Burgenson, S.A. Hild, and J.R. Reel In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone The Journal of Steroid Biochemistry and Molecular Biology 88 3 2004 277 288
22. M.F. El Etreby, and Y. Liang Effect of antiprogestins and Tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice Breast Cancer Research and Treatment 49 2 1998 109 117
23. J.G. Klijn, B. Setyono-Han, and J.A. Foekens Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer Steroids 65 10-11 2000 825 830
24. V.T. Gaddy, J.T. Barrett, J.N. Delk, A.M. Kallab, A.G. Porter, and P.V. Schoenlein Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells Clinical Cancer Research 10 15 2004 5215 5225
25. S. Vanzulli, A. Efeyan, F. Benavides, L.A. Helguero, G. Peters, J. Shen, C.J. Conti, C. Lanari, and A. Molinolo p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas Carcinogenesis 23 5 2002 749 758
26. L. Busia, H. Faus, J. Hoffmann, and B. Haendler The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression Molecular and Cellular Endocrinology 333 1 2011 37 46
27. R.L. Arnett-Mansfield, J.D. Graham, A.R. Hanson, P.A. Mote, A. Gompel, L.L. Scurr, N. Gava, A. de Fazio, and C.L. Clarke Focal subnuclear distribution of progesterone receptor is ligand dependent and associated with transcriptional activity Molecular Endocrinology 21 1 2007 14 29
28. A.H. Brodie, and H.T. Mouridsen Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy American Journal of Clinical Oncology 26 4 2003 S17 S26
29. A. Brodie Aromatase inhibitors and the application to the treatment of breast cancer J. Pasqualini, Breast Cancer: Prognosis, Treatment and Prevention 2002 Marcel Dekker NY 251 270 (Chapter 8)
30. R.D. Wiehle, K. Christov, and R. Mehta Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin Oncology Reports 18 1 2007 167 174
31. K. Ohno, N. Araki, T. Yanase, H. Nawata, and M. Iida A novel nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA Toxicological Sciences 82 2 2004 443 450
32. X. Peng, P. Jhaveri, E.A. Hussain-Hakimjee, and R.G. Mehta Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5 Carcinogenesis 28 5 2007 1000 1007
33. F. Alimirah, J. Chen, Z. Basrawala, H. Xin, D. Choubey, and DU-145 PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation FEBS Letters 580 9 2006 2294 2300
34. D. Katz, E. Ito, K.S. Lau, J.D. Mocanu, C. Bastianutto, A.D. Schimmer, and F.F. Liu Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening Biotechniques 44 2 2008 9 14
35. L. Whyte, Y.Y. Huang, K. Torres, and R.G. Mehta Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses Cancer Research 67 24 2007 12007 12017
36. X. Qi, S. Borowicz, R. Pramanik, R.M. Schultz, J. Han, and G. Chen Estrogen receptor inhibits c-Jun-dependent stress-induced cell death by binding and modifying c-Jun activity in human breast cancer cells Journal of Biological Chemistry 279 8 2004 6769 6777
37. A.F. Paul, K.C. Surinder, and P.N. Simon A therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor Clinical Cancer Research 14 2008 6469 6477
38. J.R. Pasqualini, and G. Chetrite The anti-aromatase effect of progesterone and of its natural metabolites 20alpha- and 5alpha- dihydroprogesterone in the MCF-7aro breast cancer cell line Anticancer Research 28 4B 2008 2129 2133
39. E.J. Faivre, and C.A. Lange Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells Molecular and Cellular Biology 27 2 2007 466 480
40. C. Jordan Historical perspective on hormonal therapy of advanced breast cancer Clinical Therapeutics 24 Suppl. A 2002 A3 A16
41. D.P. McDonnell, and M.E. Goldman RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism Journal of Biological Chemistry 269 16 1994 11945 11949
42. C.J. Fabian The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer International Journal of Clinical Practice 61 12 2007 2051 2063
43. S. Cassanelli, J. Louis, and D. Seigneurin Progesterone receptor heterogeneity in MCF-7 cell subclones is related to clonal origin and kinetics data Tumour Biology 16 4 1994 222 229
44. S. Chen, S. Masri, Y. Hong, X. Wang, S. Phung, Y.C. Yuan, and X. Wu New experimental models for aromatase inhibitor resistance Journal of Steroid Biochemistry and Molecular Biology 106 1-5 2007 8 15
45. S. Chen, S. Masri, X. Wang, S. Phung, Y.C. Yuan, and X. Wu What do we know about the mechanisms of aromatase inhibitor resistance? Journal of Steroid Biochemistry and Molecular Biology 102 1-5 2006 232 240
46. D. Jelovac, G. Sabnis, and J.B. Long Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole Cancer Research 65 2005 5380 5389
47. C. Lanari, C.A. Lamb, V.T. Fabris, L.A. Helguero, R. Soldati, M.C. Bottino, S. Giulianelli, J.P. Cerliani, V. Wargon, and A. Molinolo The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer Endocrine-related Cancer 16 2 2009 333 350
48. K.B. Horwitz The Molecular Biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocrine Reviews 13 2 1992 146 163
49. S. Chen An omic approach to determine the mechanisms of acquired aromatase inhibitors resistance Omics: A Journal of Integrative Biology 15 6 2011 347 352
50. M.F. Rimawi, P.B. Shetty, H.L. Weiss, R. Schiff, C.K. Osborne, G.C. Chamness, and R.M. Elledge Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes Cancer 116 5 2010 1234 1242
51. A. Carvajal, N. Espinoza, S. Kato, M. Pinto, A. Sadarangani, C. Monso, E. Aranda, M. Villalon, J.K. Richer, K.B. Horwitz, J.J. Brosens, and G.I. Owen Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75 Breast Cancer Research and Treatment 94 2 2005 171 183
52. D.X. Wen, Y.F. Xu, D.E. Mais, M.E. Goldman, and D.P. McDonnell The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells Molecular and Cellular Biology 14 12 1994 8356 8364